Stock Events

Stock Events

Spero Therapeutics 

$1.2300
53
+$0.01+0.82% 10:53 Today

Statistics

Day High
1.22
Day Low
1.215
52W High
3.08
52W Low
1.08
Volume
8,314
Avg. Volume
-
Mkt Cap
71.05M
P/E Ratio
7.78
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.55
-0.38
-0.2
-0.03
Expected EPS
-0.16
Actual EPS
N/A

Financials

11.95%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
66.8MRevenue
7.99MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SPRO. It's not an investment recommendation.
NVIDIA
8
NVDA
AMD
8
AMD
Realty Income
7
O
Amazon
7
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co. develops antibiotics and vaccines, directly competing with Spero's focus on bacterial infections.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio including anti-infectives, competing in the antibiotics market.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline has a significant presence in the antibiotics and vaccines market, overlapping with Spero's interests.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has a growing portfolio in infectious diseases, including bacterial infections, competing with Spero's pipeline.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's focus on biologics includes treatments that could compete with Spero's antibiotic therapies.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops treatments for infectious diseases, competing with Spero.
Novartis
NVS
Mkt Cap292.35B
Novartis has a diversified healthcare portfolio that includes antibiotics, directly competing with Spero Therapeutics.
Sanofi
SNY
Mkt Cap107.39B
Sanofi focuses on developing treatments for infectious diseases, including antibiotics, making it a competitor.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong presence in the infection, cardiovascular, and respiratory markets, competing with Spero's focus areas.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries has a broad generic and specialty medicine portfolio, including antibiotics, competing in the same market as Spero.

About

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Show more...
CEO
Esther Rajavelu
Employees
25
Country
United States
ISIN
US84833T1034
WKN
000A2H63F

Listings

STU
DE
2HA.STU
MU
DE
2HA.MU
MX
MX
SPRO.MX
F
DE
2HA.F

0 Comments

Share your thoughts

FAQ

What is Spero Therapeutics stock price today?▼
The current price of SPRO is $1.23 USD — it has increased by +0.82% in the past 24 hours. Watch Spero Therapeutics stock price performance more closely on the chart.
What is Spero Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Spero Therapeutics stocks are traded under the ticker SPRO.
Is Spero Therapeutics stock price growing?▼
SPRO stock has risen by +1.67% compared to the previous week, the month change is a -0.81% fall, over the last year Spero Therapeutics has showed a -42.99% decrease.
What is Spero Therapeutics market cap?▼
Today Spero Therapeutics has the market capitalization of 71.05M
When is the next Spero Therapeutics earnings date?▼
Spero Therapeutics is going to release the next earnings report on November 16, 2026.
What were Spero Therapeutics earnings last quarter?▼
SPRO earnings for the last quarter are -0.16 USD per share, whereas the estimation was -0.17 USD resulting in a +5.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Spero Therapeutics revenue for the last year?▼
Spero Therapeutics revenue for the last year amounts to 66.8M USD.
What is Spero Therapeutics net income for the last year?▼
SPRO net income for the last year is 7.99M USD.
How many employees does Spero Therapeutics have?▼
As of September 04, 2026, the company has 25 employees.
In which sector is Spero Therapeutics located?▼
Spero Therapeutics operates in the Health & Wellness sector.
When did Spero Therapeutics complete a stock split?▼
Spero Therapeutics has not had any recent stock splits.
Where is Spero Therapeutics headquartered?▼
Spero Therapeutics is headquartered in CAMBRIDGE, United States.